ATE527355T1 - Halbweiche immunstimulierende oligonukleotide der c-klasse - Google Patents

Halbweiche immunstimulierende oligonukleotide der c-klasse

Info

Publication number: ATE527355T1
Authority: AT; Austria
Prior art keywords: stimulative; immuno; oligonucleotides; soft; class semi
Prior art date: 2004-10-20

Application number

AT05858251T

Other languages

English (en)

Inventor

Arthur Krieg

Ulrike Samulowitz

Jorg Vollmer

Eugen Uhlmann

Original Assignee

Coley Pharm Group Inc

Coley Pharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-20

Filing date

2005-10-20

Publication date

2011-10-15

2005-10-20 Application filed by Coley Pharm Group Inc, Coley Pharm Gmbh filed Critical Coley Pharm Group Inc

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE527355T1 publication Critical patent/ATE527355T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000003308 immunostimulating effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Otolaryngology (AREA)
Microbiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05858251T 2004-10-20 2005-10-20 Halbweiche immunstimulierende oligonukleotide der c-klasse ATE527355T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US62075904P	2004-10-20	2004-10-20
PCT/US2005/037731 WO2006135434A2 (en)	2004-10-20	2005-10-20	Semi-soft c-class immunostimulatory oligonucleotides

Publications (1)

Publication Number	Publication Date
ATE527355T1 true ATE527355T1 (de)	2011-10-15

Family

ID=37507656

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05858251T ATE527355T1 (de)	2004-10-20	2005-10-20	Halbweiche immunstimulierende oligonukleotide der c-klasse

Country Status (28)

Country	Link
US (3)	US7566703B2 (de)
EP (1)	EP1802757B1 (de)
JP (1)	JP2008516634A (de)
KR (1)	KR20070065392A (de)
CN (1)	CN101084310A (de)
AR (1)	AR051462A1 (de)
AT (1)	ATE527355T1 (de)
AU (1)	AU2005332970A1 (de)
BR (1)	BRPI0516497A (de)
CA (1)	CA2578844A1 (de)
CR (1)	CR9131A (de)
ES (1)	ES2375071T3 (de)
GT (1)	GT200500294A (de)
IL (1)	IL182470A0 (de)
MA (1)	MA29028B1 (de)
MY (1)	MY159370A (de)
NO (1)	NO20072526L (de)
NZ (1)	NZ554753A (de)
PA (1)	PA8650101A1 (de)
PE (1)	PE20061045A1 (de)
RS (1)	RS20070164A (de)
RU (1)	RU2393223C2 (de)
SV (1)	SV2006002279A (de)
TN (1)	TNSN07150A1 (de)
TW (1)	TW200626720A (de)
UY (1)	UY29173A1 (de)
WO (1)	WO2006135434A2 (de)
ZA (2)	ZA200703609B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030109469A1 (en) *	1993-08-26	2003-06-12	Carson Dennis A.	Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US7935675B1 (en) *	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
EP0855184A1 (de) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP2002514397A (ja) *	1998-05-14	2002-05-21	コーリーファーマシューティカルゲーエムベーハー	ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
SI1077722T1 (sl)	1998-05-22	2007-02-28	Ottawa Health Research Inst	Metode in produkti za induciranje sluznicne imunosti
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
ES2572834T3 (es)	1999-02-17	2016-06-02	Csl Limited	Complejos inmunogénicos y métodos relacionados con los mismos
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
EP1296714B1 (de) *	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
ATE411054T1 (de)	2001-08-17	2008-10-15	Coley Pharm Gmbh	Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
US7276489B2 (en) *	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
EP3006043B1 (de) *	2002-04-04	2019-05-29	Zoetis Belgium S.A.	Immunostimulatorische g,u-haltige oligoribonucleotide
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
CN1753687A (zh) *	2002-10-29	2006-03-29	科勒制药集团股份有限公司	Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CA2502015A1 (en)	2002-12-11	2004-06-24	Coley Pharmaceutical Group, Inc.	5' cpg nucleic acids and methods of use
AU2004226605A1 (en) *	2003-04-02	2004-10-14	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
MXPA05013922A (es) *	2003-06-20	2006-02-24	Coley Pharm Group Inc	Antagonistas de receptor tipo toll de molecula pequena.
AU2004275876B2 (en) *	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
EP1678303A2 (de)	2003-10-30	2006-07-12	Coley Pharmaceutical GmbH	C-klasse-oligonukleotidanaloge mit verbesserter immunstimulatorischer potency
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
JP2007526253A (ja) *	2004-02-19	2007-09-13	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫刺激性ウイルスｒｎａオリゴヌクレオチド
JP2007531746A (ja) *	2004-04-02	2007-11-08	コーリーファーマシューティカルグループ，インコーポレイテッド	Ｉｌ−１０応答を誘導するための免疫活性化核酸
US20060287263A1 (en) *	2004-07-18	2006-12-21	Csl Limited	Methods and compositions for inducing antigen-specific immune responses
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
CN101171033A (zh)	2005-03-04	2008-04-30	戴纳瓦克斯技术公司	包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
US20060213010A1 (en) *	2005-03-22	2006-09-28	Davis David T	Mattress sled
JP2008535859A (ja) *	2005-04-08	2008-09-04	コーリーファーマシューティカルグループ，インコーポレイテッド	感染症によって悪化した喘息を治療するための方法
KR20080030656A (ko) *	2005-07-07	2008-04-04	콜레이 파마시티컬 그룹, 인코포레이티드	암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법
US20090214578A1 (en) *	2005-09-16	2009-08-27	Coley Pharmaceutical Gmbh	Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
CN101321868A (zh) *	2005-09-16	2008-12-10	科利制药公司	通过核苷酸修饰调节短干扰核糖核酸(siRNA)的免疫刺激特性
JP4538522B2 (ja)	2005-11-25	2010-09-08	コーリーファーマシューティカルゲーエムベーハー	免疫刺激性オリゴリボヌクレオチド
DK2405002T3 (en) *	2006-02-15	2015-01-05	Adiutide Pharmaceuticals Gmbh	Compositions and methods for oligonukleotidformuleringer
PT2078080E (pt) *	2006-09-27	2015-09-18	Coley Pharm Gmbh	Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
ES2581480T3 (es) *	2007-05-04	2016-09-06	Index Pharmaceuticals Ab	Compuestos inhibidores de crecimiento tumoral y métodos de uso de los mismos
KR20100045508A (ko)	2007-08-13	2010-05-03	콜리 파마슈티칼 게엠베하	특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 ｒｎａ 서열 모티프
WO2009143292A2 (en)	2008-05-21	2009-11-26	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating pneumoconiosis with oligodeoxynucleotides
CA2728276A1 (en) *	2008-06-18	2009-12-23	Index Pharmaceuticals Ab	Combination therapies against cancer
US20110280934A1 (en) *	2008-11-04	2011-11-17	Asa Karlsson	Increased Expression of Specific Antigens
US8053422B2 (en)	2008-12-04	2011-11-08	The United States Of America As Represented By The Department Of Health And Human Services	Anti-cancer oligodeoxynucleotides
SI2759306T1 (sl) *	2008-12-09	2016-05-31	Coley Pharmaceutical Group, Inc.	Imunostimulacijski oligonukleotidi
CN103800906B (zh)	2009-03-25	2017-09-22	德克萨斯大学系统董事会	用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
ES2641892T3 (es)	2009-08-26	2017-11-14	Selecta Biosciences, Inc.	Composiciones que inducen la ayuda de las células T
JP6025567B2 (ja) *	2009-12-16	2016-11-16	カッパーアールエヌエー，インコーポレイテッド	膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療
CA2798739A1 (en)	2010-05-26	2011-12-01	Selecta Biosciences, Inc.	Nanocarrier compositions with uncoupled adjuvant
EA201390660A1 (ru)	2010-11-05	2013-11-29	Селекта Байосайенсиз, Инк.	Модифицированные никотиновые соединения и связанные способы
KR20140050698A (ko)	2011-07-29	2014-04-29	셀렉타 바이오사이언시즈, 인크.	체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
EP2968510B1 (de)	2013-03-14	2019-10-09	President and Fellows of Harvard College	Zusammensetzungen von nanopartikeln
EP3024936B1 (de)	2013-07-25	2019-09-04	Exicure, Inc.	Sphärische nukleinsäurebasierte konstrukte als immunstimulatoren für prophylaktische und therapeutische verwendung
US10821175B2 (en)	2014-02-25	2020-11-03	Merck Sharp & Dohme Corp.	Lipid nanoparticle vaccine adjuvants and antigen delivery systems
TR201908550T4 (tr)	2014-06-04	2019-07-22	Exicure Inc	Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
WO2015200728A1 (en)	2014-06-25	2015-12-30	Selecta Biosciences, Inc.	Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
WO2016044839A2 (en)	2014-09-19	2016-03-24	The Board Of Regents Of The University Of Texas System	Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
PL3240801T3 (pl)	2014-12-31	2021-06-14	Checkmate Pharmaceuticals, Inc.	Skojarzona immunoterapia nowotworów
KR20180014009A (ko)	2015-05-29	2018-02-07	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
US10449212B2 (en)	2015-07-09	2019-10-22	National Institute For Materials Science	Immunostimulating oligonucleotide complex
US10456459B2 (en) *	2015-07-20	2019-10-29	Zoetis Services Llc	Liposomal adjuvant compositions
EP3325015B1 (de) *	2015-07-20	2021-05-12	Zoetis Services LLC	Liposomale hilfsstoffzusammensetzungen
WO2017173334A1 (en)	2016-04-01	2017-10-05	Checkmate Pharmaceuticals, Inc.	Fc receptor-mediated drug delivery
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018077385A1 (en) *	2016-10-25	2018-05-03	Biontech Rna Pharmaceuticals Gmbh	Dose determination for immunotherapeutic agents
CN108728444A (zh) *	2017-04-18	2018-11-02	长春华普生物技术股份有限公司	免疫调节性多核苷酸及其应用
US12460208B2 (en)	2017-04-18	2025-11-04	Parr Biotechnology Co., Ltd.	Immunomodulatory polynucleotides and uses thereof
US11696954B2 (en)	2017-04-28	2023-07-11	Exicure Operating Company	Synthesis of spherical nucleic acids using lipophilic moieties
WO2019160866A2 (en)	2018-02-13	2019-08-22	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt)	2018-04-09	2021-01-12	Checkmate Pharmaceuticals	Empacotamento de oligonucleotídeos em partículas similares a vírus

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5194428A (en) *	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en) *	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
US5264423A (en)	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) *	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5004810A (en) *	1988-09-30	1991-04-02	Schering Corporation	Antiviral oligomers
US5399676A (en) *	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
US5177198A (en)	1989-11-30	1993-01-05	University Of N.C. At Chapel Hill	Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5514788A (en) *	1993-05-17	1996-05-07	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of cell adhesion
US5166195A (en)	1990-05-11	1992-11-24	Isis Pharmaceuticals, Inc.	Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
ES2259800T3 (es)	1990-06-11	2006-10-16	Gilead Sciences, Inc.	Procedimientos de uso de ligandos de acido nucleico.
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
US6605708B1 (en)	1993-07-28	2003-08-12	Hybridon, Inc.	Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
US5859231A (en)	1993-09-03	1999-01-12	Duke University	Synthesis of oligonucleotides with boranophosphonate linkages
DE4338704A1 (de) *	1993-11-12	1995-05-18	Hoechst Ag	Stabilisierte Oligonucleotide und deren Verwendung
US5596091A (en) *	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US6727230B1 (en) *	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
MY114769A (en) *	1994-04-18	2003-01-31	Aviron Inc	Non-splicing variants of gp350/220
US5696248A (en)	1994-06-15	1997-12-09	Hoechst Aktiengesellschaft	3'-modified oligonucleotide derivatives
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
EP1167379A3 (de) *	1994-07-15	2004-09-08	University Of Iowa Research Foundation	Immunomodulatorische Oligonukleotide
US20030050263A1 (en) *	1994-07-15	2003-03-13	The University Of Iowa Research Foundation	Methods and products for treating HIV infection
US6160109A (en)	1995-10-20	2000-12-12	Isis Pharmaceuticals, Inc.	Preparation of phosphorothioate and boranophosphate oligomers
EP0855184A1 (de) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
WO1998037919A1 (en) *	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (de) *	1997-05-20	2007-08-22	Ottawa Health Research Institute	Verfahren zur Herstellung von Nukleinsäurekonstrukten
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1999001154A1 (en) *	1997-07-03	1999-01-14	University Of Iowa Research Foundation	Method for inhibiting immunostimulatory dna associated responses
JP4663113B2 (ja)	1997-09-05	2011-03-30	ザリージェンツオブザユニバーシティオブカリフォルニア	抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
AU760549B2 (en) *	1998-04-03	2003-05-15	University Of Iowa Research Foundation, The	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2328602A1 (en)	1998-05-06	1999-11-11	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
JP2002514397A (ja)	1998-05-14	2002-05-21	コーリーファーマシューティカルゲーエムベーハー	ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
SI1077722T1 (sl)	1998-05-22	2007-02-28	Ottawa Health Research Inst	Metode in produkti za induciranje sluznicne imunosti
JP2002521489A (ja)	1998-07-27	2002-07-16	ユニバーシティオブアイオワリサーチファウンデーション	ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
WO2000014217A2 (en)	1998-09-03	2000-03-16	Coley Pharmaceutical Gmbh	G-motif oligonucleotides and uses thereof
US6207819B1 (en)	1999-02-12	2001-03-27	Isis Pharmaceuticals, Inc.	Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
FR2790955B1 (fr) *	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6977245B2 (en) *	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
EP1177439B1 (de)	1999-04-29	2004-09-08	Coley Pharmaceutical GmbH	Screening nach modulatoren der funktion von immunstimulatorischer dna
WO2000067787A2 (en)	1999-05-06	2000-11-16	The Immune Response Corporation	Hiv immunogenic compositions and methods
EP1377554A1 (de)	1999-06-16	2004-01-07	University Of Iowa Research Foundation	Antagonismus der immunostimulatorischen cpg-oligonukleotiden durch 4-aminochinolinen und sonstigen schwachen basen
US6514948B1 (en) *	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
NZ517929A (en)	1999-09-25	2004-02-27	Univ Iowa Res Found	Immunostimulatory nucleic acids
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
AU2001227889A1 (en) *	2000-01-14	2001-07-24	The United States of America, represented by The Secretary, Department of Health & Human Services	Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en)	2000-01-20	2001-11-22	Mccluskie Michael J.	Immunostimulatory nucleic acids for inducing a Th2 immune response
CA2398432C (en)	2000-01-26	2012-06-19	Hybridon, Inc.	Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en)	2000-03-03	2002-10-24	Bratzler Robert L.	Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en)	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
EP1296714B1 (de) *	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
US20020165178A1 (en)	2000-06-28	2002-11-07	Christian Schetter	Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en)	2000-08-01	2002-12-26	Bratzler Robert L.	Nucleic acids for the prevention and treatment of gastric ulcers
US20020091097A1 (en) *	2000-09-07	2002-07-11	Bratzler Robert L.	Nucleic acids for the prevention and treatment of sexually transmitted diseases
JP2005500806A (ja)	2000-09-15	2005-01-13	コーリーファーマシューティカルゲーエムベーハー	ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
AU2001294750C1 (en)	2000-09-26	2008-09-18	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
ES2307568T3 (es)	2000-12-08	2008-12-01	Coley Pharmaceutical Gmbh	Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
WO2002053141A2 (en) *	2000-12-14	2002-07-11	Coley Pharmaceutical Group, Inc.	Inhibition of angiogenesis by nucleic acids
KR100881923B1 (ko) *	2000-12-27	2009-02-04	다이나박스 테크놀로지 코퍼레이션	면역자극 폴리뉴클레오티드 및 그것의 사용 방법
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7105495B2 (en)	2001-04-30	2006-09-12	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US20030129605A1 (en)	2001-05-04	2003-07-10	Dong Yu	Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages
EP2423335B1 (de)	2001-06-21	2014-05-14	Dynavax Technologies Corporation	Chimäre immunmodulierende Verbindungen und Verwendungsverfahren dafür
US20040132677A1 (en)	2001-06-21	2004-07-08	Fearon Karen L.	Chimeric immunomodulatory compounds and methods of using the same-IV
US20030003970A1 (en) *	2001-06-28	2003-01-02	Alan Johnson	Portable communications device
US20030148316A1 (en)	2001-08-01	2003-08-07	Lipford Grayson B.	Methods and compositions relating to plasmacytoid dendritic cells
ATE411054T1 (de)	2001-08-17	2008-10-15	Coley Pharm Gmbh	Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
CN1633598A (zh)	2001-10-05	2005-06-29	科勒制药股份公司	Toll样受体3信号传导的激动剂和拮抗剂
US20030139364A1 (en)	2001-10-12	2003-07-24	University Of Iowa Research Foundation	Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003035836A2 (en) *	2001-10-24	2003-05-01	Hybridon Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7276489B2 (en) *	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
JP4000251B2 (ja) *	2001-10-31	2007-10-31	富士通株式会社	光信号交換装置およびその制御方法
WO2003054161A2 (en) *	2001-12-20	2003-07-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US20030232443A1 (en)	2002-06-18	2003-12-18	Isis Pharmaceuticals Inc.	Antisense modulation of centromere protein B expression
EP3006043B1 (de)	2002-04-04	2019-05-29	Zoetis Belgium S.A.	Immunostimulatorische g,u-haltige oligoribonucleotide
KR101092043B1 (ko) *	2002-04-22	2011-12-12	바이오니취 라이프 사이언시즈 인코포레이티드	올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
US20040009949A1 (en) *	2002-06-05	2004-01-15	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
WO2004005476A2 (en)	2002-07-03	2004-01-15	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) *	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
WO2004007743A2 (en)	2002-07-17	2004-01-22	Coley Pharmaceutical Gmbh	Use of cpg nucleic acids in prion-disease
EP1575504A4 (de) *	2002-08-01	2009-11-04	Us Gov Health & Human Serv	Verfahren zur behandlung von entzündlichen arthropathien mit suppressoren der cpg-oligonucleotide
AR040996A1 (es) *	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
AU2003278845A1 (en)	2002-09-19	2004-04-08	Coley Pharmaceutical Gmbh	Toll-like receptor 9 (tlr9) from various mammalian species
CN1753687A (zh) *	2002-10-29	2006-03-29	科勒制药集团股份有限公司	Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CA2502015A1 (en) *	2002-12-11	2004-06-24	Coley Pharmaceutical Group, Inc.	5' cpg nucleic acids and methods of use
WO2004058159A2 (en)	2002-12-23	2004-07-15	Dynavax Technologies Corporation	Branched immunomodulatory compounds and methods of using the same
JP5102959B2 (ja) *	2002-12-23	2012-12-19	ダイナバックステクノロジーズコーポレイション	免疫刺激配列オリゴヌクレオチド及びその使用方法
CA2512484A1 (en) *	2003-01-16	2004-05-08	Hybridon, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
AU2004226605A1 (en)	2003-04-02	2004-10-14	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP1631687A2 (de)	2003-04-22	2006-03-08	Coley Pharmaceutical GmbH	Verfahren und produkte zur identifizierung und beurteilung von tlr-liganden
MXPA05013658A (es) *	2003-06-11	2006-03-02	Hybridon Inc	Oligonucleotidos inmunomoduladores estabilizados.
MXPA05013922A (es)	2003-06-20	2006-02-24	Coley Pharm Group Inc	Antagonistas de receptor tipo toll de molecula pequena.
MXPA06000619A (es) *	2003-07-15	2006-04-11	Hybridon Inc	Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
AU2004275876B2 (en) *	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
US20050215501A1 (en) *	2003-10-24	2005-09-29	Coley Pharmaceutical Group, Inc.	Methods and products for enhancing epitope spreading
EP1678303A2 (de)	2003-10-30	2006-07-12	Coley Pharmaceutical GmbH	C-klasse-oligonukleotidanaloge mit verbesserter immunstimulatorischer potency
US20050239733A1 (en)	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
CA2549173A1 (en) *	2003-12-08	2005-07-07	Hybridon, Inc.	Modulation of immunostimulatory properties by small oligonucleotide-based compounds
JP2007526253A (ja)	2004-02-19	2007-09-13	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫刺激性ウイルスｒｎａオリゴヌクレオチド
US7668561B2 (en) *	2004-02-27	2010-02-23	Qualcomm Incorporated	Apparatus and method for controlling reverse link interference among access terminals in wireless communications
CN101217973A (zh)	2004-03-12	2008-07-09	海布里顿公司	使用第二代免疫调节寡核苷酸增强的hiv疫苗活性
JP2007531746A (ja) *	2004-04-02	2007-11-08	コーリーファーマシューティカルグループ，インコーポレイテッド	Ｉｌ−１０応答を誘導するための免疫活性化核酸
US20080113929A1 (en) *	2004-06-08	2008-05-15	Coley Pharmaceutical Gmbh	Abasic Oligonucleotide as Carrier Platform for Antigen and Immunostimulatory Agonist and Antagonist
JP4942646B2 (ja) *	2004-06-15	2012-05-30	イデラファーマシューティカルズインコーポレイテッド	免疫賦活オリゴヌクレオチドマルチマー
EP1776105A2 (de)	2004-07-18	2007-04-25	Coley Pharmaceutical Group, Ltd	Verfahren und zusammensetzungen zur induzierung eigener immunantworten
US20060287263A1 (en) *	2004-07-18	2006-12-21	Csl Limited	Methods and compositions for inducing antigen-specific immune responses
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
US7569533B2 (en) *	2005-01-12	2009-08-04	Amcol International Corporation	Detersive compositions containing hydrophobic benefit agents pre-emulsified using sub-micrometer-sized insoluble cationic particles
US20080009455A9 (en) *	2005-02-24	2008-01-10	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
JP2008535859A (ja) *	2005-04-08	2008-09-04	コーリーファーマシューティカルグループ，インコーポレイテッド	感染症によって悪化した喘息を治療するための方法
AU2006241149A1 (en)	2005-04-26	2006-11-02	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US20070093439A1 (en) *	2005-10-25	2007-04-26	Idera Pharmaceuticals, Inc.	Short immunomodulatory oligonucleotides
JP4538522B2 (ja) *	2005-11-25	2010-09-08	コーリーファーマシューティカルゲーエムベーハー	免疫刺激性オリゴリボヌクレオチド
DK2405002T3 (en) *	2006-02-15	2015-01-05	Adiutide Pharmaceuticals Gmbh	Compositions and methods for oligonukleotidformuleringer
US8027888B2 (en)	2006-08-31	2011-09-27	Experian Interactive Innovation Center, Llc	Online credit card prescreen systems and methods
WO2008033432A2 (en)	2006-09-12	2008-03-20	Coley Pharmaceutical Group, Inc.	Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
PT2078080E (pt)	2006-09-27	2015-09-18	Coley Pharm Gmbh	Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
MX2009003403A (es)	2006-09-27	2009-04-09	Coley Pharm Group Inc	Composiciones de ligandos de tlr y antivirales.
AU2007353120A1 (en)	2006-10-26	2008-11-20	Coley Pharmaceutical Gmbh	Oligoribonucleotides and uses thereof
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
CN101820908A (zh) *	2007-10-09	2010-09-01	科利制药公司	包含改性糖部分的免疫刺激寡核苷酸类似物

2005
- 2005-10-18 MY MYPI20054890A patent/MY159370A/en unknown
- 2005-10-19 TW TW094136646A patent/TW200626720A/zh unknown
- 2005-10-19 UY UY29173A patent/UY29173A1/es not_active Application Discontinuation
- 2005-10-19 AR ARP050104368A patent/AR051462A1/es unknown
- 2005-10-19 GT GT200500294A patent/GT200500294A/es unknown
- 2005-10-20 WO PCT/US2005/037731 patent/WO2006135434A2/en not_active Ceased
- 2005-10-20 NZ NZ554753A patent/NZ554753A/en not_active IP Right Cessation
- 2005-10-20 ZA ZA200703609A patent/ZA200703609B/xx unknown
- 2005-10-20 RU RU2007118681/13A patent/RU2393223C2/ru not_active IP Right Cessation
- 2005-10-20 SV SV2005002279A patent/SV2006002279A/es unknown
- 2005-10-20 RS RSP-2007/0164A patent/RS20070164A/sr unknown
- 2005-10-20 US US11/255,100 patent/US7566703B2/en not_active Expired - Fee Related
- 2005-10-20 AU AU2005332970A patent/AU2005332970A1/en not_active Abandoned
- 2005-10-20 PE PE2005001231A patent/PE20061045A1/es not_active Application Discontinuation
- 2005-10-20 CN CNA2005800436842A patent/CN101084310A/zh active Pending
- 2005-10-20 ES ES05858251T patent/ES2375071T3/es not_active Expired - Lifetime
- 2005-10-20 CA CA002578844A patent/CA2578844A1/en not_active Abandoned
- 2005-10-20 JP JP2007538026A patent/JP2008516634A/ja not_active Withdrawn
- 2005-10-20 BR BRPI0516497-4A patent/BRPI0516497A/pt not_active Application Discontinuation
- 2005-10-20 KR KR1020077008882A patent/KR20070065392A/ko not_active Withdrawn
- 2005-10-20 AT AT05858251T patent/ATE527355T1/de not_active IP Right Cessation
- 2005-10-20 EP EP05858251A patent/EP1802757B1/de not_active Expired - Lifetime
- 2005-10-20 PA PA20058650101A patent/PA8650101A1/es unknown
2007
- 2007-04-11 IL IL182470A patent/IL182470A0/en unknown
- 2007-04-19 TN TNP2007000150A patent/TNSN07150A1/fr unknown
- 2007-05-16 NO NO20072526A patent/NO20072526L/no not_active Application Discontinuation
- 2007-05-17 MA MA29915A patent/MA29028B1/fr unknown
- 2007-05-18 CR CR9131A patent/CR9131A/es not_active Application Discontinuation
2008
- 2008-04-30 ZA ZA200803752A patent/ZA200803752B/xx unknown
- 2008-12-17 US US12/336,986 patent/US7795235B2/en not_active Expired - Fee Related
2010
- 2010-09-14 US US12/881,475 patent/US20110201672A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20072526L (no)	2007-07-20
US7566703B2 (en)	2009-07-28
NZ554753A (en)	2010-03-26
WO2006135434A2 (en)	2006-12-21
EP1802757B1 (de)	2011-10-05
AR051462A1 (es)	2007-01-17
US20110201672A1 (en)	2011-08-18
CA2578844A1 (en)	2006-12-21
SV2006002279A (es)	2006-07-07
BRPI0516497A (pt)	2008-09-09
KR20070065392A (ko)	2007-06-22
ZA200803752B (en)	2010-03-31
US20060140875A1 (en)	2006-06-29
ES2375071T3 (es)	2012-02-24
AU2005332970A1 (en)	2006-12-21
IL182470A0 (en)	2007-09-20
US7795235B2 (en)	2010-09-14
PE20061045A1 (es)	2006-11-07
EP1802757A2 (de)	2007-07-04
PA8650101A1 (es)	2006-08-03
MY159370A (en)	2016-12-30
CR9131A (es)	2007-10-22
US20090137519A1 (en)	2009-05-28
RS20070164A (sr)	2009-01-22
RU2393223C2 (ru)	2010-06-27
TW200626720A (en)	2006-08-01
CN101084310A (zh)	2007-12-05
MA29028B1 (fr)	2007-11-01
WO2006135434A3 (en)	2007-05-10
GT200500294A (es)	2006-04-05
RU2007118681A (ru)	2008-11-27
JP2008516634A (ja)	2008-05-22
ZA200703609B (en)	2008-10-29
TNSN07150A1 (en)	2008-11-21
UY29173A1 (es)	2006-05-31

Legal Events

Date	Code	Title	Description
2012-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE527355T1 (de)	2011-10-15	Halbweiche immunstimulierende oligonukleotide der c-klasse
DE602005022897D1 (de)	2010-09-23	Piperidinylamino-thienoä2,3-dü-pyrimidinverbindungen
EP1791567A4 (de)	2009-12-23	Chemisch modifizierte oligonucleotide
ATE469145T1 (de)	2010-06-15	4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
NL1028967A1 (nl)	2005-11-08	4-Fenylamino-chinazoline-6-yl-amiden.
NO20051522D0 (no)	2005-03-22	Kabelskjotbeskytter.
FR2871075B1 (fr)	2015-09-11	Catalyseur
DE602007001681D1 (de)	2009-09-03	1,3-dioxan-carboxylsäuren
FI20041113A0 (fi)	2004-08-25	Aksiaalivuoinduktiosähkökone
NO20053210D0 (no)	2005-06-30	Linneslakkompensator.
NO20041374L (no)	2005-10-03	Bolgekraftverk.
NO20040762L (no)	2005-08-22	Stromskinne.
DE502004006772D1 (de)	2008-05-21	Wirkwerkzeug-Barre
NO20052746D0 (no)	2005-06-08	Avlopsenhet.
DK1907574T3 (da)	2014-01-20	Oligonukleotider
DE602005012919D1 (de)	2009-04-09	Brillenendstück
DE202004017327U1 (de)	2005-04-07	Fitnessrad
NO20052482D0 (no)	2005-05-23	Redningskokong.
AT500198B8 (de)	2007-02-15	Ladewagen
AT500249A3 (de)	2006-03-15	Scheibenegge
DE602005026899D1 (de)	2011-04-28	Bildaufzeichungselement
NL1025196A1 (nl)	2004-02-24	Hark-Zeef-Vork.
NL1028622A1 (nl)	2005-09-27	Stelwig.
FR2867906B1 (fr)	2006-06-02	Repartiteur
ES1057865Y (es)	2005-01-16	Desatascador de desagues.